AIMD Ainos Inc

$AIMD announced new semiconductor front-end orders, a $2.1M back-end subscription program and a 1B-plus chemical dataset.

$AIMD Sometimes smalls wins outweighs the potential gains associated with parabolic plays. Risk management is key to consistently winning

$AIMD did i just read something about 1 billion smell data?? wtf lol thats an absurd number

$AIMD is showing an interesting shift from validation toward commercialization. VASRO research highlights Ainos’ AI Nose platform gaining momentum in semiconductor applications, with its front end program moving into initial commercial orders and a 2.1M back end subscription program providing an early revenue benchmark. Add in Ainos’ proprietary chemical dataset with 1B+ records and its broader Chemical Intelligence strategy, and the company has multiple potential avenues for growth as commercialization develops. $AIMD is one to watch closely.

$AIMD anyone find how many units were part of this deal? It seems as though they did not release that yet but not sure why.

$AIMD Ainos AI Nose is expanding its data foundation through deployments in semiconductor manufacturing environments.

$AIMD Over 1.32 this will start to move nice. Curling hard from demand ranges when you zoom out

$AIMD chewed through the 5k shares at $1.41 , looking for that $1.50 break and hold on the 5 min for more continued upside. Yesterdays news was solid and i dont think the current share price and volume reflects that

$AIMD what a wild day. This is just the start. Bright future ahead here with multiple revenue streams and hopefully many more to Come!🍻

$AIMD BioPhoenix is a clinical-stage biotechnology company dedicated to advancing innovative therapies that address significant unmet medical needs. Our pipeline spans immunology, oncology, and ophthalmology, with programs progressing from translational research through global clinical development.

$AIMD Ainos Secures Three Japanese Robotics Patents, Advancing Chemical Perception for the Physical AI Era

$AIMD Next-gen AI Nose dropped with better reliability, they keep improving the platform while deployed

$AIMD recent news that was positive in cased you missed it.. Share price dropped but it's Friday so $1.50+ on tap Ainos Completes Required Data Delivery And Technology Transfer Under Its VELDONA License Deal For $600K Initial License Payment BENZINGA 8:10 AM ET 9/30/2026

$AIMD looks like that 10k wall at $1.50 yesterday moved down to $1.39.. someone needs some lunch money to close out the week. currently not much resistance after that..

$AIMD let’s get a huge October. September we received some great news on new partnerships and payments received. Let’s end the year strong!!💪

$AIMD I like the capital allocation here. They can keep more money and management attention on chemical intelligence while VELDONA moves forward with outside funding

$AIMD The biggest thing for me is the 600k near term license payment. It gives veldona a concrete monetization point

$AIMD the risk reward around veldona looks better after td's PR with the clearer near term payment

$AIMD this deal makes the story cleaner lowkey. AI Nose stays the main growth focus while the partner takes on much of the veldona development burden

$AIMD entered an exclusive license with BioPhoenix for its VELDONA platform, covering Sjögren's disease and thrombocytopenia, up to $10M.